Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

NCT03214562 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

High Risk Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
BIOLOGICAL: Filgrastim
DRUG: Fludarabine
DRUG: Idarubicin
BIOLOGICAL: Pegfilgrastim
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]